Peter Nash

Rheumo, Golfer(pathetic), Caravaggisti, Prof School of Medicine Griffith University, A/Prof Univ. of Qld, Director Rheumatology Research Unit Sunshine Coast,

[Peter Nash @drpnash]

OP002 (2026)
ANIFROLUMAB TREATMENT IN PATIENTS WITH SJÖGREN’S DISEASE: EFFICACY AND SAFETY ASSESSMENT IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIA PROOF-OF-MECHANISM TRIAL (ANISE-II) anifrolumab works in SjD - high interferon signature works the best? #EULAR2026

[Peter Nash @drpnash]

POS0773 (2025)
LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS TREATED WITH BIMEKIZUMAB: LONG-TERM RESULTS FROM PHASE 2B/3 TRIALS
- 5000 pt yrs AxSpA & PsA - low uveitis rates - bime or selection? #bimekizumab #uveitis #AxSpA #PsA

[Peter Nash @drpnash]

POS0109 (2025)
COMPARATIVE PERSISTENCE AND EFFECTIVENESS OF IXEKIZUMAB VERSUS OTHER b/tsDMARD CLASSES IN REAL-WORLD PsA TREATMENT: 12-MONTH RESULTS FROM THE PRO-SPIRIT STUDY - a practical comparison #ixekizumab #TNF #IL23i

[Peter Nash @drpnash]

OP0096 (2025)
Sonelokimab, IL-17A- & IL-17F- Nanobody, outcomes PsA: Ph 2 ARGO trial
SLK 60mg n=41 SLK 120mg n=43 ADA ref n=42
MDA(n/%) 25 (61.0). 22 (51.2). 19 (45.2)
nanobody effective- question is same or better? #IL17 #nanobody #sonelokimab

[Peter Nash @drpnash]

OP0091 (2025)
MARKERS OF IL-17 SIGNALLING IN THE BLOOD OF PATIENTS WITH PSORIATIC ARTHRITIS WITH INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS
interesting - 17F raised in TNF non-responders PsA - #IL17F #PsA #TNF-IR

[Peter Nash @drpnash]

12 mths AbA delays RA up to 3 yrs esp if high titre ACPA

[Peter Nash @drpnash]

Hence the Emery editorial in Rheumatology journal - biosimilar Toci from day 1 #RA #Tocilizumab #MTX

[Peter Nash @drpnash]

stratify for gender baseline clinical trials https://t.co/W0yMFkPkqS

[Peter Nash @drpnash]

no excuses https://t.co/Cwr48a8TFy

[Peter Nash @drpnash]

Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ... https://t.co/uig8ryG44A need the best for IMIDs

[Peter Nash @drpnash]

BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection | New England Journal of Medicine https://t.co/8x5PGZAyE2 Doesnt protect.

[Peter Nash @drpnash]

Varenna, M., Zucchi, F., Di Taranto, R. et al. Osteoclast in CRPS: an alleged guilty fully acquitted. Osteoporos Int 36, 737–740 (2025). https://t.co/LaqqkYOcjv its not the Osteoclast! but perhaps dependent on acute vs chronic changes

[Peter Nash @drpnash]

From DNA to PGA
David Pisetsky, MD, PhD
May 07, 2025
📷
Investigating the mechanisms of antinuclear antibody (ANA) expression in SLE since 1978..MTP session on the Type 1 & 2 model for SLE - relevant for CAR-T &
D2T vs C2M in SLE as well as RA PsA AxSpA #RheumNow # SLE #D2T

[Peter Nash @drpnash]

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis | New England Journal of Medicine https://t.co/ECFov2bhg3 FDA approved now #GCA #Upadcitinib

[Peter Nash @drpnash]

A new toxicity syndrome in patients with autoimmune disease treated with CAR T-cell therapy - The Lancet Rheumatology https://t.co/zi0ZLDGqv7 We need comparative studies! #CAR-T #LICATS

[Peter Nash @drpnash]

i have been using once a month risedronate post denosumab cessation - here zoledronate useful alternative https://t.co/fuGETvDQjl

[Peter Nash @drpnash]

worth considering for our joint replacement patients https://t.co/JRWQWsEvSH

[Peter Nash @drpnash]

Human Papillomavirus Vaccination and Actinic Keratosis Burden https://t.co/x5sCFXxqao affects many of our patients MTX, TNFs, JAKs + QLD sun ! #IMID #HPVvax #RheumNow

[Peter Nash @drpnash]

@MithuRheum @RheumOnePagers @Lupus_Chat @LupusResearch @LupusInitiative @CaringForLupus @LADAOrg @CreakyJoints needs head to head against full dose rituximab not placebo

[Peter Nash @drpnash]

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | New England Journal of Medicine https://t.co/YK7CDxc1xj not seen in IMID CAR-T cell therapy yet but instructive nevertheless